A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

Redasemtide has a plausible path because this is a randomized, double-blind, placebo-controlled Phase 2b study using Day 90 modified Rankin Scale, which is the standard functional endpoint in stroke and clinically meaningful if it wins. But acute ischemic stroke is a hard development setting: outcomes are noisy, baseline severity and treatment timing matter enormously, and background standard-of-care can overwhelm modest drug effects. The study also spans two distinct cohorts: patients not receiving reperfusion and patients eligible for or already treated with thrombolysis/mechanical recanalization. That broadens relevance, but it also adds heterogeneity that can dilute efficacy and complicate analysis unless stratification and powering are very strong, which are not described here. No prior efficacy signal, effect size assumption, or sample-size context is provided to materially de-risk the readout. Primary completion has just passed while status is still active not recruiting, which adds some operational and disclosure-timing uncertainty. Net, the design is solid, but the intrinsic odds of a clearly positive result look below 50%.

Redasemtide had a positive Japan Phase 2 result (n=150) showing ~2x improvement in mRS ≤2 rates vs placebo, which is encouraging. However, several factors temper optimism: (1) Regulators required this additional Phase 2b dose-finding study rather than allowing a direct Phase 3, suggesting the prior signal was not robust enough. (2) Acute ischemic stroke neuroprotection/neurorepair is one of the hardest therapeutic areas with a long history of Phase 2 successes failing in larger confirmatory trials (e.g., NXY-059, NA-1). (3) This 2b trial is larger (627 pts), multinational, tests two doses plus placebo, and includes a new Cohort B (patients eligible for reperfusion therapy) — all adding heterogeneity. (4) The novel MOA (MSC mobilization) lacks deep mechanistic validation in stroke. (5) No results have been disclosed despite primary completion date passing. Base rate for Phase 2 stroke trials succeeding is ~25-30%; the prior positive result lifts this modestly, but global replication risk is substantial.

This is a Phase 2b trial for acute ischemic stroke, a challenging indication with historically low success rates. The trial uses mRS at Day 90 as the primary endpoint, which is clinically meaningful but stroke trials face high variability. The two-cohort design adds complexity - Cohort A targets patients ineligible for standard therapies while Cohort B includes those receiving standard care, potentially diluting treatment effect in Cohort B. Without prior efficacy data for Redasemtide and the inherent difficulties in acute stroke intervention, Phase 2 stroke trials typically show modest success. Given the binary positive outcome question, the intrinsic probability of success appears below 50%.

The trial's design is complex, splitting patients into cohorts based on eligibility for standard recanalization therapy. This introduces heterogeneity and may dilute the treatment effect signal. The primary endpoint, mRS at 90 days, is a standard and validated functional outcome measure for stroke, which is a strength. However, the intrinsic probability is tempered by the high-risk nature of stroke trials, the challenging patient population in Cohort A (ineligible for standard therapy), and the fact this is a Phase 2b study primarily focused on dose-finding and signal detection rather than definitive efficacy. The sponsor, Shionogi, is credible. The primary completion date has just passed, so results are imminent, adding disclosure risk. Overall, the trial hurdles suggest a likelihood below 50%.

Solid phase 2b randomized double-blind placebo-controlled design minimizes bias. Primary endpoint mRS score at day 90 is the gold-standard functional outcome for AIS trials, typically analyzed as ordinal shift or favorable dichotomization (mRS 0-2), with established sensitivity. Patient population spans two cohorts: Cohort A (thrombolysis/MT ineligible) and Cohort B (eligible/received SOC), broadening applicability but risking heterogeneity in baseline severity and effect sizes. No prior data in trial fields, but advancement to 2b implies phase 1/2a safety/efficacy signals. AIS neuroprotection/remyelination space has high failure rate (~10-20% phase 2 success historically) due to narrow therapeutic windows, placebo responses, and endpoint noise. Sponsor Shionogi has strong operational track record in neurology. Status active not recruiting with primary completion imminent (-2 days) indicates good enrollment/execution, low dropout risk. Disclosure risk minimal absent anomalies. Balanced design lifts odds above base rate, but indication challenges and cohort complexity cap at 32% positive (beats placebo).

This Phase 2b acute ischemic stroke trial by Shionogi evaluates redasemtide, a neuroprotectant, against placebo across two cohorts: one without recanalization therapy access (Cohort A) and one with standard care (Cohort B). The primary endpoint is the modified Rankin Scale (mRS) at Day 90, a well-established functional outcome measure. While the dual-cohort design broadens the eligible population, it introduces significant heterogeneity, potentially diluting treatment effects. Historically, neuroprotective agents have faced high failure rates in stroke due to narrow therapeutic windows and poor penetration, raising skepticism despite encouraging preclinical data. The trial status is 'Active Not Recruiting' with primary completion estimated March 31, 2026; given the run date is April 2026, topline data is imminent. However, without prior Phase 2a dose-finding success publicly disclosed, efficacy uncertainty remains high. The probability of a statistically significant positive result is estimated at 35%, reflecting the challenging indication history.

This Phase 2b acute ischemic stroke trial completed enrollment with primary completion just 2 days ago, meaning data is likely unblinded to sponsor but not yet public. The 90-day mRS endpoint requires full follow-up before database lock and analysis. Stroke neuroprotection trials have historically high failure rates—over 100 agents have failed despite promising preclinical data. Redasemtide is a novel biologic with no prior Phase 2 efficacy data disclosed. The two-cohort design (thrombolysis-ineligible vs eligible) adds complexity and potential for mixed results. Shionogi has not pre-announced any interim analyses or positive signals, suggesting standard timeline. Acute stroke trials face substantial heterogeneity in patient outcomes due to lesion size, time-to-treatment, and comorbidities. Without mechanistic validation in humans or biomarker evidence, the intrinsic probability of achieving statistically significant mRS improvement remains below 40%. The sponsor's silence at completion date marginally increases concern versus early positive disclosure.

Redasemtide (S-005151) is being evaluated in a 680-patient Phase 2b acute ischemic stroke (AIS) trial. Stroke is a notoriously difficult indication for CNS drugs, with high historical failure rates in Phase 2b/3. However, this program carries a uniquely favorable setup: a prior placebo-controlled Phase 2 trial in Japan showed a robust absolute improvement in 90-day mRS <=2 (34% for the active dose vs. 18% for placebo). Furthermore, an April 2025 interim futility analysis successfully cleared the 1.5 mg/kg dose in the non-reperfused cohort (Cohort A), while dropping the lower 0.75 mg/kg dose, indicating the trial isolated the active dose and remains viable. A key risk is the inclusion of Cohort B (patients receiving endovascular thrombectomy), which could dilute the overall efficacy signal if the drug's marginal benefit is lower in reperfused patients. Moreover, single-country Phase 2a AIS results frequently fail to replicate globally. Nonetheless, given the large sample size, clear dose-response optimization, and the previously demonstrated 16% absolute efficacy delta, the likelihood of statistical success on the primary mRS endpoint leans positive. I estimate the intrinsic YES probability at 56%.

The trial is in Phase 2b, which is an early stage of development. The primary endpoint is the Modified Rankin Scale (mRS) Score at Day 90, which is a well-established measure for stroke outcomes. However, the sample size and cohorts' specific details are not provided, making it difficult to assess the trial's power to detect a significant effect. The intervention, redasemtide, is a biological agent, which may have a favorable safety profile but also carries inherent risks. The current status is 'Active Not Recruiting,' indicating that patient enrollment is complete, but results are not yet available. Given these factors, a 40% probability of a positive outcome seems reasonable, reflecting moderate uncertainty.